In mice tumor models (including colon cancer), the use of antibodies against the IL-10 receptor (anti-IL-10R) combined with CpG-oligodeoxynucleotides (ODN), which is a ligand for TLR9, is linked to stimulation of macrophages, tumor-associated myeloid monocytes, DCs, and to release of TNF-α, CXCL-10, IL-12, and IL-1. Here, TNF is linked to neoplasm.